0001493152-23-042663.txt : 20231124
0001493152-23-042663.hdr.sgml : 20231124
20231124160008
ACCESSION NUMBER: 0001493152-23-042663
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231120
FILED AS OF DATE: 20231124
DATE AS OF CHANGE: 20231124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Finley John David
CENTRAL INDEX KEY: 0001851034
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33672
FILM NUMBER: 231436700
MAIL ADDRESS:
STREET 1: C/O SENECA BIOPHARMA, INC.
STREET 2: 20271 GOLDENROD LANE
CITY: GERMANTOWN
STATE: MD
ZIP: 20876
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PALISADE BIO, INC.
CENTRAL INDEX KEY: 0001357459
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 522007292
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7750 EL CAMINO REAL, SUITE 5200
CITY: CARLSBAD
STATE: CA
ZIP: 92009
BUSINESS PHONE: (858) 704-4900
MAIL ADDRESS:
STREET 1: 7750 EL CAMINO REAL, SUITE 5200
CITY: CARLSBAD
STATE: CA
ZIP: 92009
FORMER COMPANY:
FORMER CONFORMED NAME: Seneca Biopharma, Inc.
DATE OF NAME CHANGE: 20200127
FORMER COMPANY:
FORMER CONFORMED NAME: Neuralstem, Inc.
DATE OF NAME CHANGE: 20060324
4
1
ownership.xml
X0508
4
2023-11-20
0
0001357459
PALISADE BIO, INC.
PALI
0001851034
Finley John David
7750 EL CAMINO REAL, SUITE 2A
CARLSBAD,
CA
92009
1
1
0
0
CEO, CFO, Director
0
Common Stock, par value $0.01
2023-11-20
5
A
0
E
10000
0.51
A
57781
D
Common Stock, par value $0.01
777
I
By FCW Investments, LLC
Restricted Stock Units
2023-11-21
4
A
0
38000
0.00
A
Common Stock
38000
38000
D
Common Stock Options
0.59
2023-11-21
4
A
0
45000
0.00
A
2033-11-21
Common Stock
45000
45000
D
Shares were purchased pursuant to the Palisade Bio, Inc. 2021 Employee Stock Purchase Plan, as amended ("ESPP") for the ESPP purchase period from July 1, 2023 through November 20, 2023. In accordance with the ESPP, the shares were purchased in a transaction exempt under Rule 16b-3(c) at a price equal to 85% of the closing price of the issuer's common stock on November 20, 2023.
Reporting Person is the managing member of FCW Investments LLC and has the sole investment and voting power over the securities held by this entity.
The Grants were made as discretionary grants to Reporting Person from the Issuer's 2021 Equity Incentive Plan, as amended ("Plan"). Pursuant to Nasdaq rules, no shares may be issued pursuant to the grants until such time as there are sufficient shares of common stock available under the Plan. The applicable vesting for each grant is subject to the Reporting Person continuing to be a service provider to Issuer at the time of vesting.
Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
The grant vests in twelve (12) equal quarterly installments over a three (3) year period with the first vesting date to occur on February 6, 2024.
N/A.
Each option represents the right to purchase one share of common stock at the exercise price.
The grant vests in twelve (12) equal quarterly installments over a three (3) year period from the grant date.
/s/ JD Finley
2023-11-24